Unum Therapeutics Inc (NASDAQ:UMRX)’s share price was down 5.4% during trading on Monday . The stock traded as low as $0.69 and last traded at $0.70, approximately 569,835 shares changed hands during trading. An increase of 295% from the average daily volume of 144,412 shares. The stock had previously closed at $0.74.

Several equities research analysts recently commented on UMRX shares. Morgan Stanley cut their target price on Unum Therapeutics from $8.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research report on Monday, August 12th. HC Wainwright restated a “buy” rating on shares of Unum Therapeutics in a research report on Tuesday, August 13th. Wedbush cut their target price on Unum Therapeutics from $20.00 to $13.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. They noted that the move was a valuation call. Finally, Zacks Investment Research upgraded Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Saturday, November 9th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $8.30.

The business has a 50 day moving average of $1.12 and a two-hundred day moving average of $1.99. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.96 and a current ratio of 1.96. The firm has a market capitalization of $21.59 million, a price-to-earnings ratio of -0.51 and a beta of 1.01.

Unum Therapeutics (NASDAQ:UMRX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.07). Unum Therapeutics had a negative return on equity of 96.07% and a negative net margin of 388.07%. The firm had revenue of $1.02 million for the quarter, compared to analyst estimates of $4.41 million. On average, equities analysts predict that Unum Therapeutics Inc will post -1.42 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its stake in Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock worth $85,000 after buying an additional 18,717 shares during the period. Wedbush Securities Inc. purchased a new stake in shares of Unum Therapeutics in the third quarter worth approximately $48,000. Paloma Partners Management Co purchased a new stake in shares of Unum Therapeutics in the second quarter worth approximately $227,000. Jane Street Group LLC purchased a new stake in shares of Unum Therapeutics in the second quarter worth approximately $132,000. Finally, Susquehanna International Group LLP purchased a new stake in shares of Unum Therapeutics in the second quarter worth approximately $62,000. 43.02% of the stock is currently owned by institutional investors and hedge funds.

About Unum Therapeutics (NASDAQ:UMRX)

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Featured Article: How Do I Invest in Dividend Stocks

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.